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1. Introduction 
A growing body of research suggests that anemia is independently associated with 
morbidity and mortality in the general population as well as in patients with chronic 
diseases where the prevalence of anemia is high (1-4). Anemia prognosis depends on the 
underlying cause of the anemia. However, the severity of the anemia, its etiology, and the 
rapidity with which it develops can each play a significant role in the prognosis. Similarly, 
the age of the patient and the existence of other co-morbid conditions influence outcome. 
Higher mortality rates are almost always observed in patients with anemia. Many studies (5-
11) identified anemia as an independent factor impacting mortality and provided the 
evidence that management of anemia, independent of other risk factors, improves mortality 
rates. In one study (3), independent of the underlying disease, anemia was associated with 
increased mortality in chronic kidney disease, congestive heart failure and acute myocardial 
infarction patients; increased morbidity in chronic kidney disease, congestive heart failure 
and cancer radiotherapy patients; and decreased quality of life in chronic kidney disease 
and cancer patients. In addition to its impact upon mortality, anemia also significantly 
influences morbidity. Multiple studies support this assertion especially in patients with 
chronic kidney disease and heart failure (12-17).  
2. Morbidity and mortality among patients with certain types of anemia 
2.1 Aplastic anemia 
In the early 1930s aplastic anemia was considered almost inevitably fatal. However, the 
morbidity and mortality of this disease have decreased dramatically since the introduction 
of bone marrow transplantation and immunosuppressive therapy. Survival figures in 
aplastic anemia from several studies have shown biphasic curves, with the highest mortality 
rates within the first 6 months after diagnosis. Five-year survival rates have been described 
to range from 70% to 90% and to be similar among patients treated with either bone marrow 
transplantation or immunosuppression (18). Patients who undergo bone marrow 
transplantation have additional issues related to toxicity from the conditioning regimen and 
graft versus host disease (19). With immunosuppression, approximately one third of 
patients does not respond. For the responders, relapse and late-onset clonal disease, such as 
paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, and leukemia, are risks 
(20). In one retrospective institutional analysis, predictors for response to 
immmunosuppresion at 6 months were younger age, higher baseline absolute reticulocyte, 




responders to 53% in the non responders (21). Two factors determines the clinical outcome in 
aplastic anemia, the severity of the pancytopenia and patient age. In a retrospective review 
from the European Group for Blood and Marrow Transplantation (EBMT), the relative risk for 
a poor outcome following immunosuppressive treatment was 3.4 for patients with  very 
severe anemia and 1.5 in those with severe anemia compared with less severe cases. In the 
EBMT, the 5-year survival rate varied inversely and significantly with age. Also, at any degree 
of severity, the outcome was worse in older patients. The increase in mortality in the older 
patients was mainly due to infection or bleeding. Most infections were acquired from 
endogenous microbial flora of the skin and gastrointestinal tract (22).  
2.2 Vitamin B12 deficiency anemia 
Pernicious anemia is associated with a two- to threefold excess risk of intestinal-type gastric 
cancer but, the actual degree of risk varies with the duration of disease and geographic 
location. Pernicious anemia is also associated with an increased risk of gastric carcinoid 
tumors, presumably due to prolonged achlorhydria with compensatory hypergastrinemia, 
and argyrophilic cell hyperplasia. There is also a suggested excess of oesophageal cancer 
among these patients (23). In the analysis of the Oxford Vegetarian Study (24), low vitamin 
B12 intake could explain the increased death rate (2.2 times) from mental and neurological 
diseases among vegetarians compared to non-vegetarians. Specific neurologic problems 
associated with vitamin B12 deficiency consist of subacute combined degeneration of the 
dorsal (posterior) and lateral spinal columns, axonal degeneration of peripheral nerves and 
central nervous system symptoms including memory loss, irritability, and dementia (25).  
In some cases, B12-deficient dementia may be misdiagnosed as Alzheimer's disease (26). The 
cognitive decline in older subjects associated with subclinical vitamin B12 deficiency is 
difficult to explain but a role for increased homocysteine level is possible. People with 
Alzheimer's disease were found to have elevated homocysteine, reduced B12, or reduced 
folate levels (27). On the other hand studies found elevated homocysteine to be associated 
with risk of Alzheimer's disease (26). Selhub et al. (27) analyzed data from 8,083 people, 
including whites, blacks, and Hispanics. They found that elevated homocysteine levels (> 
11.4 µmol/l for men, > 10.4 µmol/l for women) were associated with B12 levels less than 338 
pg/ml. A level of 430 pg/ml provides a safety factor for homocysteine and other potential 
problems. Elevated homocysteine is associated with increased mortality, with an increased 
risk of 33% per 5 µmol/l increase in homocysteine (28,29) with increased  risk for coronary 
artery, cerebrovascular, and peripheral vascular diseases and venous thrombosis (30). A 
2008 meta-analysis of vitamin supplementation and cognitive function found little benefit to 
people already diagnosed with dementia, but did improve cognition in elderly people with 
elevated homocysteine but who were not diagnosed with dementia (31). Another 2008 study 
found that vitamin supplementation did not slow cognitive decline in people with mild to 
moderate Alzheimer's disease (32). 
Vitamin B12 deficiency appears to be associated with an increased risk of osteoporosis 
(33,34), and hip and spine fractures (35), possibly due to suppression of osteoblast activity 
(36,37). Even subtle degrees of B12 deficiency may be associated with bone loss (38), 
although this has not been shown in all studies (39). Supplementation with vitamin B12 and 
folate has been shown to reduce hip fractures in a group of elderly Japanese patients with 
residual hemiplegia after an ischemic stroke. However, there is insufficient data to 
recommend this therapeutic approach in other populations at high risk for fracture. 
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2.3 Folic acid deficiency anemia 
Studies found that both maternal plasma folate and vitamin B12 are independent risk factors 
for neural tube defects (40). In a literature review, Ray et al examined 8 studies that 
demonstrated that folate deficiency was a risk factor for placental abruption/infarction (41). 
Several observational and controlled trials have shown that neural tube defects can be 
reduced by 80% or more when folic acid supplementation is started before conception (42). 
In countries like the United States and Canada, the policy of widespread fortification of 
flour with folic acid has proved effective in reducing the number of neural tube defects (43). 
Although the exact mechanism is not understood, a relative folate shortage may exacerbate 
an underlying genetic predisposition to neural tube defects. Diminished folate status is 
associated with enhanced carcinogenesis. A number of epidemiologic and case-control 
studies have shown that folic acid intake is inversely related to colon cancer risk (44). With 
regard to the underlying mechanism, Blount et al showed that folate deficiency can cause a 
massive incorporation of uracil into human DNA leading to chromosome breaks (45). 
Another study by Kim et al suggested that folate deficiency induces DNA strand breaks and 
hypomethylation within the p53 gene (46). Low folate and high homocysteine levels are a 
risk factor for cognitive decline in high-functioning older adults (47) and high homocysteine 
level is an independent predictor of cognitive impairment among long-term stay geriatric 
patients (48). Despite the association of high homocysteine level and poor cognitive 
function, homocysteine-lowering therapy using supplementation with vitamins B-12 and B-
6 was not associated with improved cognitive performance after two years in a double-
blind, randomized trial in healthy older adults with elevated homocysteine levels (49). 
2.4 Thalassemia  
Iron excess in patients with thalassemia is associated with early death if untreated. Several 
publications provide evidence that the heart is unquestionably the most critical organ 
affected by iron jeopardizing survival of thalassemia patients. In a study of 97 thalassemia 
patients (50), 36% of patients between the ages of 15 and 18 showed detectable cardiac iron, 
the risk of cardiac disease increases as patient’s age increases. For the full cohort, the 
estimated survival without cardiac disease was 80% after 5 years of chelation therapy, 65% 
after 10 years and only 55% after 15 years. At the New York Academy of Sciences, Seventh 
Symposium on Thalassemia (51), the causes of death reported in 240 thalassemia major 
patients in Italy born between 1960-1984 were cardiac disease (71%), infections (12%), liver 
(6%) and other causes (11%). Another review of information available to the Cooley’s 
Anemia Foundation shows that 11% of its 724 registered patients (77 total) died over the 
time period January 1999 – July 31, 2008. The data demonstrate that heart disease in these 
young patients remains the leading cause by far.  
Since 1999, there has been a marked improvement in survival in thalassaemia major in the 
UK (52), similar change with improved survival has been reported from Italy (53,54) and 
Cyprus (55). This improvement has been mainly driven by a reduction in deaths due to 
cardiac iron overload. The most likely causes for this include the introduction of T2* cardiac 
magnetic resonance imaging technique to quantify myocardial iron overload and 
appropriate intensification of iron chelation treatment, alongside other improvements in 
clinical care. With a reduction in deaths from iron overload, infection may become a leading 
cause of death in thalassaemia in the future. Splenectomy increases risk of infection with 
Pneumococcus and Haemophilus influenzae and deferoxamine therapy increases risk of 




infections. However, the most frequently isolated organism was Klebsiella. An increased 
risk of Klebsiella infection in thalassaemia has previously been reported from South East 
Asia (56,57), and some forms of Klebsiella can use deferoxamine as an iron source (58), but it 
remains to be clarified whether Klebsiella infection is related to iron chelation therapy. 
Hepatocarcinoma is also a growing problem for hepatitis C positive patients, and improved 
antiviral treatments are needed. Fortunately, transmission of hepatitis C by blood 
transfusion is now very rare, so this risk may be limited to older patients (52).  
2.5 Sickle cell anemia  
The greatest burden of sickle cell anemia (SCA) is in sub-Saharan Africa (SSA), and 
estimates suggest that 50–80% of these patients will die before adulthood (59). Identification 
of risk factors has led to improved survival through targeted interventions. In the West, 
reported risk factors for death include infections, low hemoglobin and fetal hemoglobin 
(HbF), high white blood cell count and hemolysis (60-62). Comprehensive care includes 
prompt treatment of acute events and prophylaxis against infections, mainly with oral 
penicillin and vaccination against Streptococcus pneumoniae. Countries that have introduced 
these interventions have achieved significant reductions in mortality; with up to 94% 
surviving to 18 years in the USA (63) and 99% to 20 years in the UK (64). In most African 
countries, the lack of an evidence-base has led to inertia in terms of implementation of these 
interventions, such as penicillin prophylaxis. In Africa, available mortality data are sporadic 
and incomplete. Many children are not diagnosed, especially in rural areas, and death is 
often attributed to malaria or other comorbid conditions (65). The  mortality rates in SCA 
amongst a hospital-based cohort in Tanzania (66) was 1.9 per 100 PYO which is similar to 3 
per 100 PYO reported from the USA before use of penicillin prophylaxis (67), with the 
highest incidence of death was in the first 5 years of life. Evidence from previous research 
suggests that infection is the most likely cause of death in this period, with the proportion 
of deaths from infection reported to be 50% in the USA (60, 68), 28% in Jamaica (69) and 
20% in Dallas (63). The prevention of pneumococcal infection with penicillin and the 
introduction of pneumococcal conjugate vaccine has been shown to be effective in 
reducing mortality (70) with improved survival rates of 84% in Jamaica (69), 86% by 18 
years in Dallas (64) and 99% in London (65). One review reported 42% reduction in 
mortality in SCA in USA, 0 to 3 years old, between two eras, 1995–1998 and 1999–2002 
(71). There is compelling justification for implementation of these interventions in Africa 
to prevent deaths due to infections (65,66).  
Sudden death is not uncommon among SCA patients. A retrospective/prospective review 
of 21 autopsy cases from sickle cell patients who died suddenly between 1990 and 2004 
demonstrated higher-than-expected percentages of acute and chronic sickle cell-related lung 
injury such as fat embolism (33.3%) and pulmonary hypertension (33.3%), with right 
ventricular hypertrophy (33.3%) (72). In Sickle cell trait (SCT) under unusual circumstances 
serious morbidity or mortality can result from complications related to polymerization of 
deoxy-hemoglobin S. Although rare, sudden death is the most serious complication of sickle 
cell trait. SCT has a substantially increased age-dependent risk of exercise-related sudden 
death as in military basic training and civilian organized sports. A retrospective review of 
all soldiers in basic training found that those with SCT had a 40-fold increased risk of 
sudden exertional death (73). Sudden death may occur in susceptible persons when poor 
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physical conditioning, dehydration, heat stresses or hypoxic states precipitate sickling of the 
abnormal erythrocytes. Most of the death mechanisms are related to the biological 
consequences of diffuse microvascular occlusion due to sickling, although a significant 
number of such sudden deaths remain unexplained after thorough autopsy. Rare 
mechanisms encountered include acute splenic sequestration (74). Other problems may also 
be encountered in SCT patients including increased urinary tract infection in women, gross 
hematuria, complications of hyphema, splenic infarction with altitude hypoxia or exercise 
and life-threatening complications of exertional heat illness (exertional rhabdomyolysis, heat 
stroke, or renal failure). In addition, some disease associations have been noted with sickle 
cell trait which might not result from polymerization of hemoglobin S but from linkage to a 
different gene mutation. There is an association with renal medullary carcinoma, early end 
stage renal failure in autosomal dominant polycystic kidney disease, and surrogate end 
points for pulmonary embolism (75).  
2.6 Paroxysmal nocturnal hemoglobinuria 
Most patients with paroxysmal nocturnal hemoglobinuria (PNH) die from venous 
thrombotic events. Stroke is a common cause of morbidity and mortality in PNH and it is 
almost exclusively a result of cerebral venous thrombosis. Case reports of ischemic stroke 
complicating PNH have implicated a similar propensity for arterial events caused by the 
disease. PNH is a rare cause of arterial stroke with reported 9 cases but it should be 
considered in young stroke patients with abnormal blood findings (76).  
3. Morbidity and mortality of anemia in high risk groups 
3.1 Effect of anemia on maternal mortality and morbidity 
Maternal anemia is a ubiquitous pregnancy complication, and has been associated with an 
array of adverse perinatal and reproductive outcomes. It is estimated that 20% of maternal 
deaths in Africa can be attributed to anemia. In combination with obstetric hemorrhage, 
anemia is estimated to be responsible for 17–46% of cases of maternal death (77). A review of 
symptoms associated with maternal deaths in Bangladesh led researchers to conclude that 
anemia had played a secondary role in nearly all cases (78). Estimates of maternal mortality 
resulting from anemia range from 34/100,000 live births in Nigeria to as high as 194/100,000 
in Pakistan (79). The risk of death is greatly increased with severe anemia. There is little 
evidence of increased risk associated with mild or moderate anemia. Viteri (80) reported 
that anemic pregnant women are at greater risk of death during the perinatal period and 
that anemia is the major contributory or sole cause of death in 20–40% of the 500 000 
maternal deaths/year. A study from Indonesia illustrated the much higher risk of maternal 
death in anemic women from rural areas than from urban areas, possibly as a result of 
problems with timely access to obstetric care (81). On the basis of the evidence available, it 
seems reasonable to assume that the risk of maternal mortality is greatly increased with 
severe anemia. The data available only confirm an associative—not a causal—relationship. 
Nevertheless, the strength of this relationship makes it appropriate to presume that it is 
causal. It must also be noted that there are currently no agreed international standards or 
sets of criteria for attributing death to anemia (82). Except in South Asia and Papua New 
Guinea, the reported rates of severe anemia do not appear to exceed 10% of pregnant 




hemoglobin concentration <100 g/L was 70.0/10000 deliveries compared with 19.7/10000 
deliveries for non-anemic women (81). However, the authors believed that the relation of 
maternal mortality with anemia reflected a greater extent of hemorrhage and late arrival at 
admission rather than the effect of a prenatal anemic condition. In another study, 
approximately one-third of the anemic women had megaloblastic anemia due to folic acid 
deficiency and two-thirds had hookworm. The cutoff for anemia was extremely low (<65 g 
hemoglobin/L), and the authors stated that although anemia may have contributed to 
mortality, it was not the sole cause of death in many of the women (83). It has been suggested 
that maternal deaths in the puerperium may be related to a poor ability to withstand the 
adverse effects of excessive blood loss, an increased risk of infection, and maternal fatigue; 
however, these potential causes of mortality have not been evaluated systematically (84). 
Maternal morbidity resulting from anemia includes diminished work capacity and 
physical performance have been reported as a result mostly of iron deficiency anemia. 
Anemia leads to abnormalities in host defense and neurological dysfunction. Increased 
risks of premature labor and low birth weight have also been reported in association with 
anemia in pregnancy (80).  
3.2 Effect of anemia on infant mortality and morbidity 
There is substantial evidence that maternal iron deficiency anemia increases the risk of 
preterm delivery and subsequent low birth weight, and accumulating information suggests 
an association between maternal iron status in pregnancy and the iron status of infants 
postpartum. Preterm infants are likely to have more perinatal complications, to be growth-
stunted, and to have low stores of iron and other nutrients. Lower birth weights in anemic 
women have been reported in several studies (85-87). In one study, the odds for low birth 
weight were increased across the range of anemia, increasing with lower hemoglobin in an 
approximately dose-related manner (88). Welsh women who were first diagnosed with 
anemia (hemoglobin <104 g/L) at 13–24 wk of gestation had a 1.18–1.75-fold higher relative 
risk of preterm birth, low birth weight, and prenatal mortality (89). After controlling for 
many other variables in a large Californian study, Klebanoff et al., (90) showed a doubled 
risk of preterm delivery with anemia during the second trimester but not during the third 
trimester. In Alabama, low hematocrit concentrations in the first half of pregnancy but 
higher hematocrit concentrations in the third trimester were associated with a significantly 
increased risk of preterm delivery (91). When numerous potentially confounding factors 
were taken into consideration, analysis of data from low-income, predominantly young 
black women in the United States showed a risk of premature delivery (<37 wk) and 
subsequently of having a low-birth-weight infant that was 3 times higher in mothers with 
iron deficiency anemia on entry to care (92). Similar relations were observed in women from 
rural Nepal, in whom anemia with iron deficiency in the first or second trimester was 
associated with a 1.87-fold higher risk of preterm birth, but anemia alone was not (88). In an 
analysis of 3728 deliveries in Singapore, 571 women who were anemic at the time of 
delivery had a higher incidence of preterm delivery than did those who were not anemic 
(93). An association between maternal anemia and lower infant Apgar scores was reported 
in some studies. In 102 Indian women in the first stage of labor, higher maternal hemoglobin 
concentrations were correlated with better Apgar scores and with a lower risk of birth 
asphyxia (94). In the Jamaican Perinatal Mortality Survey of >10000 infants in 1986, there 
was an ≈50% greater chance of mortality in the first year of life for those infants whose 
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mothers had not been given iron supplements during pregnancy (95). Trials that included 
large numbers of iron-deficient women showed that iron supplementation improved birth 
weight (86,96) and Apgar scores (97). In rural populations in China antenatal 
supplementation with iron-folic acid was associated with longer gestation and a reduction 
in early neonatal mortality compared with folic acid. Multiple micronutrients were 
associated with modestly increased birth weight compared with folic acid, but, despite this 
weight gain, there was no significant reduction in early neonatal mortality (98). 
3.3 Effect of anemia on children and adolescents mortality and morbidity  
Apart from previously mentioned morbidity and mortality from hereditary anemia among 
children, by far the most common cause of anemia in this age group is chronic iron 
deficiency anemia (IDA). There is reasonably good evidence that mental and motor 
developmental test scores are lower among infants with IDA. Although some aspects of 
cognitive function seem to change with iron therapy, lower developmental IQ and 
achievement test scores have still been noted after treatment. A variety of non-cognitive 
alterations during infant developmental testing has also been observed, including failure to 
respond to test stimuli, short attention span, unhappiness, increased fearfulness, withdrawal 
from the examiner, and increased body tension. Exploratory analyses suggest that such 
behavioral abnormalities may account for poor developmental test performance in infants 
with IDA. There has been a steady accumulation of evidence that IDA limits maximal 
physical performance, sub-maximal endurance, and spontaneous activity in the adult, 
resulting in diminished work productivity with attendant economic losses. However, it is 
important to consider that studies that attempt to separate indicators of malnutrition, such 
as iron deficiency, from other types of environmental deprivation may be inappropriately 
separating factors that occur together naturally and that therefore cannot be differentiated 
(99). The behavioral effects of IDA may be due to changes in neurotransmission. In a recent 
review that focuses on human studies, short- and long-term alterations associated with iron 
deficiency in infancy can be related to major dopamine pathways (100). It is widely accepted 
that long-term consequences of iron deficiency are often irreversible. Several studies have 
found that reversal of the anemia did not improve standardized test scores (101,102). One 
study (103) examined a group of Costa Rican children at five years of age. Children who had 
moderately severe IDA (hemoglobin less than 10 g per dL [100 g per L]) in infancy scored 
significantly lower on standardized tests at five years of age, despite a return to normal 
hematologic status and growth.  
However, there is accumulating evidence for the potential benefits of preventing iron 
deficiency in infancy and treating it before it becomes chronic or severe. A recent study (104) 
of the preschool-aged Chinese children found that children who had chronic IDA in infancy 
displayed less positive social and emotional development. In contrast, the behavior and 
affect of children whose anemia was corrected before the age of 24 months were comparable 
to those of children who were non-anemic throughout infancy. The persistence of poorer 
cognitive, motor, affective, and sensory system functioning during childhood highlights the 
need to prevent iron deficiency in infancy and to find interventions that lessen the long-term 
effects of this widespread nutrient disorder.  
Iron deficiency is also implicated in such neurologic sequelae as irritability, lethargy, 




abnormalities. Although only a few cases (30 cases) in the literature support the association 
between IDA and increased intracranial tension, it may be more common than previously 
thought. The underlying mechanisms remain unknown, but cerebral venous thrombosis 
should be carefully excluded (105). Rarely has iron deficiency been recognized as a 
significant cause of stroke in the adult or pediatric populations (106,107). One case series 
reported 6 children, 6 to 18 months of age, who presented with an ischemic stroke or venous 
thrombosis after a viral prodrome. All patients had iron deficiency as a consistent finding 
among the group, and other known etiologies of childhood stroke were excluded (108)  
3.4 Effect of anemia on mortality and morbidity in elderly people 
In the past decade, anemia has been associated with a number of negative outcomes in 
elderly people. In a report from the Netherlands, community-dwelling subjects older than 
85 years with anemia had higher 5-year mortality rates than subjects with normal 
hemoglobin levels (109,110). In a cohort of older women with mild-to-moderate physical 
disability, Chaves et al noted an increase in mortality associated with hemoglobin levels less 
than 110 g/L (111). In a study of 1744 community-dwelling persons aged 71 years or older, 
anemia is independently associated with increased mortality over 8 years for both races and 
sex. Anemia also is a risk factor for functional and cognitive decrease (1). 
In an analysis of 5888 community-dwelling older adults enrolled in the Cardiovascular 
Health Study (2), anemia was associated with increased risk for hospitalization and 
mortality in older adults. In another community-based study of more than 17 000 older 
adults more than 66 years (4), anemia was significantly associated with risk for all-cause 
hospitalization, hospitalization secondary to cardiovascular disease, and all-cause mortality. 
In both studies, the association between hemoglobin and mortality was not linear; with the 
risk for death increased at both extremes of hemoglobin. As this risk occurs at hemoglobin 
levels that are currently considered normal, consideration should be given to refining the 
current definition of anemia in older adults to reflect this continuum of risk (2, 4). 
Not only anemia in elderly is a strong predictor of death, it has also been associated with 
various conditions such as decreased physical performance, disability in daily living, 
mobility disabilities, cognitive impairment, depression, falls and fractures, frailty, admission 
to hospital and diminished quality of life (112-114). However in the presence of common 
comorbidities among elderly, anemia could be considered as a risk marker rather than a risk 
factor. In the Leiden 85-plus Study (115), a population-based  prospective follow-up study of 
562 people aged 85 years, anemia in very elderly people was found to be associated with an 
increased risk of death, independent of comorbidity. However, the associated functional 
decline appears to be attributed mainly to comorbidity. 
3.5 Effect of anemia on mortality and morbidity in patients with cancer 
Anemia is common in cancer patients, although the prevalence is influenced both by the 
type of malignancy and the choice of treatment. Individual studies have compared the 
survival of patients with and without anemia and have shown reduced survival times in 
patients with various malignancies associated with anemia including carcinoma of the lung, 
cervix, head and neck, prostate, lymphoma, and multiple myeloma. A systemic, quantitative 
review in 2001 (116) estimated the overall increase in risk of death with anemia to 65% (CI: 
54-77%). In addition, an intriguing association has also been observed between anemia and 
disease progression among patients undergoing radiotherapy, particularly in those with 
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cervical carcinoma or with squamous cell carcinoma of the head and neck. Harrison et al 
found that two thirds of women with cervical carcinoma are anemic at baseline, and 82% are 
anemic during radiotherapy (117). Correlations between anemia, tumor tissue oxygenation, 
local recurrence, and survival have been demonstrated in other studies (118,119). In one 
study including cases of head and neck cancer, 75% of patients undergoing combined 
chemotherapy and radiotherapy become anemic (120) and anemia has been associated with 
worse local regional control and survival rates (121). However, there is presently little 
evidence that anemia treatment per se impacts the tumor response to chemotherapy alone. 
3.6 Effect of anemia on mortality and morbidity in patients with cardiac diseases 
Substantial evidence suggests that anemia is an independent risk factor for worse outcomes 
in patients with heart failure (CHF) and ischemia heart disease including myocardial 
infarction. Anemia is a common comorbidity in CHF. Compared with nonanemic patients 
the presence of anemia also is associated with worse cardiac clinical status, more severe 
systolic and diastolic dysfunction, a higher beta natriuretic peptide level, increased 
extracellular and plasma volume, a more rapid deterioration of renal function, a lower 
quality of life, and increased medical costs (122-129).  
In a systematic review and meta-analysis published in 2008, after a minimal follow-up of 6 
months, 46.8% of anemic patients died compared with 29.5% of non-anemic patients 
irrespective to the cause of CHF. In studies that analyzed hemoglobin as a continuous 
variable, a 1-g/dL decrease in hemoglobin was independently associated with significantly 
increased mortality risk (130). 
The associations between hemoglobin and outcomes was studied in 2653 patients 
randomized in the CHARM Program in the United States and Canada. Anemia was 
common in heart failure, regardless of left ventricular ejection fraction (LVEF). Lower 
hemoglobin was associated with higher LVEF yet was an independent predictor of adverse 
mortality and morbidity outcomes (131). On the contrary, a large nationally representative 
study of older patients in the United States hospitalized with HF demonstrated no graded 
relationship between lower hematocrit values and increased mortality and suggest that 
although anemia is an independent predictor of hospital readmission, its relationship with 
increased mortality in HF patients is largely explained by the severity of comorbid illness. 
The authors suggest that anemia may be predominantly a marker rather than a mediator of 
increased mortality risk in older patients with HF (132). 
In heart failure, the causes of anemia and the associations between anemia and outcomes 
are probably multiple and complex. The anemia in CHF mainly is caused by a 
combination of renal failure and CHF-induced increased cytokine production, and these 
can both lead to reduced production of erythropoietin (EPO), resistance of the bone 
marrow to EPO stimulation, and to cytokine-induced iron-deficiency anemia caused by 
reduced intestinal absorption of iron and reduced release of iron from iron stores. The use 
of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers also may 
inhibit the bone marrow response to EPO. Hemodilution caused by CHF also may cause a 
low hemoglobin level (129). The potential mechanisms linking anemia to increased 
mortality risk in CHF have not been characterized but may be related to changes in 
ventricular loading conditions and cardiac structure, altered neurohormonal activation, or 
reduced free radical scavenging capacity. It is also possible that anemia is a marker of 
more severe underlying myocardial disease (133). 
In several controlled and uncontrolled studies, correction of the anemia with subcutaneous 




associated with an improvement in clinical status, number of hospitalizations, cardiac and 
renal function, and quality of life. However, larger, randomized, double-blind, controlled 
studies still are needed to verify these initial observations. The effect of EPO may be related 
partly to its nonhematologic functions including neovascularization; prevention of 
apoptosis of endothelial, myocardial, cerebral, and renal cells; increase in endothelial 
progenitor cells; and anti-inflammatory and antioxidant effects (129). 
In ischemic heart disease, both advanced age and the presence of flow-limiting coronary 
stenosis markedly impaired cardiac compensatory response to anemia, even without 
concomitant acute myocardial injury. These conditions, among other limits to the patients' 
physiologic reserve, may explain why levels of hemoglobin tolerated by younger 
individuals would not be tolerated by the elderly. They may also explain why elderly 
patients with acute myocardial infarction represent a group at extremely high risk for death, 
despite infarct sizes similar to those of younger patients (3).  
The clinical utility of blood transfusion in anemic cardiovascular disease populations is 
controversial. According to the guidelines from the American College of Physicians and the 
American Society of Anesthesiology, the “transfusion threshold” for patients without 
known risk factors for cardiac disease is a hemoglobin level in the range of 6 to 8 g/dL. In 
one study, patients hospitalized with acute myocardial infarction, blood transfusion was 
associated with a significantly lower 30-day mortality rate among patients with a hematocrit 
<30% on admission (134). But in 838 critically ill patients (26% with cardiovascular disease), 
maintaining hemoglobin at 10 to 12 g/dL did not provide additional benefits on 30-day 
mortality compared with maintaining hemoglobin at 7 to 9 g/dL (135). Blood transfusion 
may be associated with other adverse effects including immunosuppression with increased 
risk of infection, sensitization to HLA antigens, and iron overload. Given this profile of risks 
and benefits, transfusion may be considered as an acute treatment for severe anemia on an 
individualized basis but does not appear to be a viable therapeutic strategy for the long-
term management of chronic anemia in CHF (135,136). 
Pilot studies have found that in a large number of HF patients it’s safe to raise hemoglobin 
with erythropoietin-stimulating therapies and there is a suggestion that raising hemoglobin 
in anemic HF patients may lead to improved outcomes (136). A prospective, randomized 
trial studied the treatment of anemia in patients with moderate-to-severe CHF (NYHA class 
III to IV) whose left ventricular ejection fraction was less than 40% of normal. Patients who 
received treatment had a 42.1% improvement in NYHA class, compared with the control 
cohort who had a decrease of 11.4%. Number of hospital days, need for diuretic therapy, 
and renal function impairment were all significantly greater in the control group than in the 
treated group (137). 
The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is a large multicenter, 
randomized, double-blind, placebo-controlled trial. In this study treatment of anemia with 
erythropoiesis-stimulating agents (ESAs) (darbepoetin alfa) was not associated with 
significant clinical benefits. But in the post hoc analysis of outcomes among the treated 
group, an increase of 1.0 g/dL or more in hemoglobin is required to achieve benefit in 
reduction of all-cause mortality or heart failure-related hospitalization (138). However, 
further observational and experimental studies are needed to help identify optimal 
treatment algorithms for both ESAs and iron that maximize clinical benefit while 
minimizing adverse outcomes. A pragmatic approach to the care of patients with HF needs  
definitive anemia treatment goals that are dynamic and disease specific, rather than those 
that adopt a more simplistic hemoglobin-specific approach. 
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3.7 Effect of anemia on mortality and morbidity in patients with end stage renal 
diseases 
Anemia is associated with higher mortality rates and possibly heart disease in patients with 
kidney disease. However, the available evidence is limited as concluded in a systematic 
literature review published in 2006 (139). In a retrospective review (140) of nearly 20 000 of 
patients undergoing maintenance hemodialysis, hemoglobin levels of 8.0 g/dL or less were 
associated with a 2-fold increase in odds of death when compared with hemoglobin levels 
ranging between 10.0 and 11.0 g/dL. A similar study (141) of nearly 100 000 hemodialysis 
patients confirmed that a hematocrit higher than 30% was associated with a lower mortality. 
Compared with patients with a hematocrit higher than 30%, the overall relative risk of death 
was between 33% and 51% higher for the group with a hematocrit less than 27%, and 
between 12% and 20% higher for the group with a hematocrit of 27% to 30%, with and 
without adjustments for severity of disease. Subsequent analyses have determined that 
hematocrit levels maintained between 33% and 36% were associated with the lowest risk of 
death (142). Another study showed that in patients undergoing maintenance hemodialysis, 
the risk of hospitalization declines with hematocrit improvement, with a 16% to 22% lower 
hospitalization rate for patients with hematocrit values between 36% and 39% compared 
with patients with hematocrits between 33% and 36% (12). Also, prospective clinical trials of 
patients with end-stage renal disease have demonstrated a relationship among hematocrit, 
left ventricular dilatation, and left ventricular hypertrophy (LVH) (13-17,143).  
The optimal management of anemia in patients with end-stage renal disease is controversial. 
Appropriate use of ESAs and intravenous iron can effectively manage the anemia of chronic 
kidney disease and end-stage renal disease (ESRD) (144-146), several randomized trials have 
reported an increased risk of mortality and cardiovascular events in patients treated to 
achieve higher hematocrit levels (145-147). A large cohort of incident US hemodialysis 
patients found that dialysis units that treated severe anemia more aggressively with ESAs 
and intravenous iron had a one-year mortality rate that was 5 percent lower than in units 
that treated more conservatively. But the same aggressive treatment for milder anemia 
brought a 10 percent increase in the rate of mortality (147).  
3.8 Effect of anemia on mortality and morbidity in patients with end stage renal 
diseases and heart failure 
Anemia also may play a role in increasing cardiovascular morbidity in chronic kidney 
insufficiency, diabetes, renal transplantation, asymptomatic left ventricular dysfunction, left 
ventricular hypertrophy, acute coronary syndromes including myocardial infarction and 
chronic coronary heart disease, and in cardiac surgery. Renal failure, cardiac failure, and 
anemia therefore all interact to cause or worsen each other--the so-called cardio-renal-
anemia syndrome (129). The reciprocal relationships among these 3 components of 
cardiorenal anemia have been the subject of a number of trials with inconsistent and 
sometimes paradoxic results (148). Cardiovascular disease (CVD) is a significant 
complication in chronic kidney disease (CKD) and a major cause of death in dialysis 
patients. Clinical studies have shown that anemia is associated with reduced survival in 
patients with renal disease, heart failure or both. Low haemoglobin (Hb) has been identified 
as an independent risk factor for LV growth in CKD patients, suggesting that there is a 
direct link between anemia and adverse cardiac outcomes. This suggests that correction of 
anemia may improve prognosis. In patients with chronic kidney disease and CHF, treatment 




prevents left ventricular dilatation (152); and increases left ventricular ejection fraction, (153-
154), stroke volume, and cardiac output (153). 
The evidence for an association between anemia and an increased risk of adverse 
cardiovascular outcomes in patients with CKD is strong. The relationship between anemia and 
adverse outcomes is complex. While it is likely to be indirect to some extent, evidence also 
suggests that there may be a causal link between low hemoglobin levels and the development 
of CVD. Treatment of anemia with epoetin has been shown to improve cardiac function and to 
produce regression of LVH in CKD patients, whether or not they are receiving dialysis. 
Furthermore, consistent treatment with epoetin before the initiation of dialysis is associated 
with a reduced risk of developing cardiac disease in patients with CKD. Normalizing Hb 
levels in patients with advanced CVD has a limited effect on changes in LV geometry, 
however, and – at least under certain circumstances –may increase their risk of death. The 
degree of CVD could affect other factors, such as vascular reactivity, which may determine 
whether partial or full correction of anemia is appropriate for a particular individual (154).  
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